 |
PDBsum entry 1nfw
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Molecular structures of human factor xa complexed with ketopiperazine inhibitors: preference for a neutral group in the s1 pocket.
|
 |
|
Authors
|
 |
S.Maignan,
J.P.Guilloteau,
Y.M.Choi-Sledeski,
M.R.Becker,
W.R.Ewing,
H.W.Pauls,
A.P.Spada,
V.Mikol.
|
 |
|
Ref.
|
 |
J Med Chem, 2003,
46,
685-690.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
The structures of the noncovalent complex of human factor Xa (fXa) with four
non-peptide inhibitors containing a central sulfonylpiperazinone scaffold have
been determined to about 2.1 A resolution. Highly potent fXa inhibitors
containing both neutral groups such as chlorobenzothiophene or chlorothiophene
and basic groups such as benzamidine were shown to interact in the S1 pocket
through the neutral group whereas the S4 pocket is occupied by the basic moiety.
The scaffold comprising the sulfonyl keto piperazine moiety might play a pivotal
role in the orientation of substituents, since there is a strong hydrogen bond
between Gly219 of fXa and the carbonyl oxygen of the piperazine. This unique
"reverse" binding mode is heretofore unreported in fXa and shows that
electrostatic interactions in the S1 subsite are not an absolute requirement to
maintain high affinity. Selectivity against other serine proteases can be
readily explained in light of these structural results. It has opened up new
prospects for designing fXa inhibitors with increased oral bioavailability.
|
 |
|
|
|
|
 |